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The analysis of genomic distribution of retroviral vectors is a powerful tool to
monitor ‘vector-on-host’ effects in gene therapy (GT) trials but also provides
crucial information about ‘host-on-vector’ inﬂuences based on the target cell
genetic and epigenetic state. We had the unique occasion to compare the
insertional proﬁle of the same therapeutic moloney murine leukemia virus
(MLV) vector in the context of the adenosine deaminase-severe combined
immunodeﬁciency (ADA-SCID) genetic background in two GT trials based on
infusions of transduced mature lymphocytes (peripheral blood lymphocytes, PBL)
or a single infusion of haematopoietic stem/progenitor cells (HSC). We found that
vector insertions are cell-speciﬁc according to the differential expression proﬁle
of target cells, favouring, in PBL-GT, genes involved in immune system and T-cell
functions/pathways as well as T-cell DNase hypersensitive sites, differently from
HSC-GT. Chromatin conformations and histone modiﬁcations inﬂuenced integ-
ration preferences but we discovered that only H3K27me3 was cell-speciﬁcally
disfavoured, thus representing a key epigenetic determinant of cell-type depen-
dent insertion distribution. Our study shows that MLV vector insertional proﬁle is
cell-speciﬁc according to the genetic/chromatin state of the target cell both in
vitro and in vivo in patients several years after GT.
INTRODUCTION
Retroviral vectors have been extensively used in gene therapy
(GT) applications as an effective tool to permanently integrate a
therapeutic gene of interest into a target cell, conferring in most
cases stable and efﬁcient transgene expression over time (Kohn
& Candotti, 2009; Naldini, 2009). Both wild-type retroviruses
and retroviral vectors were initially thought to insert randomly
into the host genome, but it is now well established that the
majority of them display a semi-random or a non-random
integration proﬁle possibly inﬂuencing the fate of transduced
cells (Brady et al, 2009; Bushman, 2007; Cattoglio et al, 2007;
Ciufﬁ, 2008; Mitchell et al, 2004; Wu et al, 2003). Initial reports
of leukaemia cases from the X-linked severe combined
immunodeﬁciency (SCID-X1) GT clinical trial suggested a
potential link between leukaemogenesis and insertional activa-
tion of the LMO2 proto-oncogene (Hacein-Bey-Abina et al,
2003a,b). Indeed, it is now recognized that vector bearing
enhancer sequences can alter the expression of neighbouring
genes (Maruggi et al, 2009) and several studies associated
events of clonal dominance in vivo to vector insertion sites
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hand, in vitro analyses of transduced clones puriﬁed from
patients several years after GT failed to show clear signs of
perturbation ofneighbouring genes (Cassanietal, 2009;Recchia
et al, 2006). Additionally, although the analyses of integration
sites from adenosine deaminase deﬁcient SCID (ADA-SCID),
SCID-X1, and chronic granulomatous disease (CGD) trials
(Aiuti et al, 2007; Deichmann et al, 2007; Ott et al, 2006) show
the presence of speciﬁc regions with recurrent integrations
(common integration sites, CIS), it remains undeﬁned to what
extent the presence of CIS is the result of positive clonal
selection after cell infusion or instead derives from preferential
targeting for integration at the time of transduction (Cattoglio
et al, 2007). Indeed, insertion site selection during in vitro
transduction could be driven by tethering of transcription
factors (TF) to speciﬁc regions according to TF binding
sites location (Felice et al, 2009) and seems dependent on
cellular determinants as wellas onvector design (Lewinski etal,
2006).
Along this line, we studied the impact of vector integrations
on clonal expansion and the frequency of CIS after GT in ﬁve
patients from a clinical trial of haematopoietic stem cell gene
therapy(HSC-GT)forADA-SCID thathas beenshowntoachieve
immune and metabolic correction in the absence of adverse
events related to gene transfer (Aiuti et al, 2002a, 2009). Our
data did not reveal any sign of clonal dominance or aberrant
expansions even in the presence of CIS in the LMO2 or CCND2
proto-oncogene loci (Aiuti et al, 2007). It is now believed that
other factors including the disease background, the nature ofthe
transgene, and the acquisition of other genetic abnormalities
unrelated to vector insertions are also needed for aberrant
expansion of transduced clones (Hacein-Bey-Abina et al, 2008;
Howe et al, 2008). While most of these studies have been
focusing on vector-on-host effects, there is still limited
information on the role of the target cell status at the time of
transduction and host-on-vector inﬂuences upon in vivo
engraftment. Toward this aim, two recent publications
addressed the possible inﬂuence of target cell type on
integration proﬁle of retroviral vectors in murine LSK
subpopulations (Kustikova et al, 2009) and T-cells (Newrzela
et al, 2008), the latter suggesting that the cell-dependent
insertional pattern of transduced, mature murine lymphocytes
play only a secondary role in inducing resistance to transforma-
tion. However, these ﬁndings remain tobe deﬁned inGT clinical
trials on patient samples and a characterization of genomic
features inﬂuencing integration preferences in different human
target cells is currently missing. New information now provide
a detailed genome-wide map of the epigenetic and chromatin
state of different human cell types, like HSC and peripheral
blood T-cells, allowing to compare retroviral vector distribution
with several high-throughput mapped genomic features such as
DNase I hypersensitive sites (HSS; Boyle et al, 2008; Xi et al,
2007) and histone methylation distribution (Barski et al, 2007;
Cui et al, 2009). In this regard, recent reports have shown an
interesting correlation between retroviral insertions and histone
methylations in human cells (Brady et al, 2009; Wang et al,
2007, 2010).
In order to study the inﬂuences of host cell condition on
vector insertion sites in vitro and after clonal selection in
patients, we identiﬁed integration sites from patients affected by
ADA-SCID and treated with infusions of moloney murine
leukemia virus (MLV) transduced HSC (HSC-GT) or peripheral
blood lymphocytes (PBL-GT; Aiuti et al, 2002b). This
represents a unique model that allows the comparison of
insertions derived from the same ADA-encoding vector in the
context of the same genetic background but in two different
target cells, before and several years after infusion in patients.
We found that the MLV-derived vector displayed a different
integration distribution in the two groups of patients under
PBL-GT or HSC-GT. These cell-speciﬁc insertion preferences
were directly related to the epigenetic state and expression
proﬁle of the cell type at the time of transduction and overall
did not show any particular vector-driven bias in patients even
long-term after GT.
RESULTS
Distribution of vector integrations from PBL-GT and HSC-GT
To compare the insertional proﬁle of MLV vector in PBL-GT and
HSC-GT, we identiﬁed a total of 4157 unique insertions from
ADA-SCID patients (2198 from PBL-GT and 1959 from HSC-GT)
by the combination of shotgun cloning-generated insertion
libraries of ligation mediated PCR (LM-PCR) products and
pyrosequencing of linear ampliﬁcation mediated PCR (LAM-
PCR) products (Table 1). The integrations were divided in two
categories according to the samples from which they were
collected for each group of patients, in vitro (PRE-GT) and in
vivo (POST-GT). From HSC-GT patients, we retrieved retroviral
integration sites (RIS) from both CD3þ T-cells and CD15þ
granulocytes in vivo, whereas only T-cells were analysed in the
PBL-GT group since in these patients the vector is undetectable
in other lineages. The overall distribution of the vector
integrants conﬁrmed the classical preferences of MLV vector
to integrate inside or in the proximity of coding regions
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Table 1. Amounts of unique integration sites retrieved through LM-PCR/
LAM-PCR from PBL-GT and HSC-GT in vitro pre-transplant (PRE-GT) and
in vivo after transplant (POST-GT)
Patient samples Pt1 Pt2 Pt3 Pt4
PBL-GT (2198 unique integrations)
T cells (PRE-GT) pre-infusion 669 121 451 124
T cells (POST-GT) 6–9 years after last infusion 40 22 669 102
% of vector positive T cells 1.8 1.4 100 0.7
Patient samples Pt4 Pt5 Pt6 Pt7
HSC-GT (1959 unique integrations)
CD34R cells (PRE-GT) pre-infusion NA NA 558 329
T cells (POST-GT) 3–6 years after GT 85 204 300 382
% of vector positive T cells 52.6 100 100 69.8
Granulocytes (POST-GT) 3–6 years after GT 6 24 71 NA
% of vector positive granulocytes 1.1 5.8 3.4 NA
Percentagesof vector positive cells in vivoat last followup, measuredthrough
Q-PCR as copies of vector per cell genome, are also reported for each patient
(NA¼not available).
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in a window of 10kb surrounding the transcription start site
(TSS) of genes, while in HSC-GT their frequency was 46.1 and
21.8%, respectively.
Comparing the data obtained in vitro before infusion and in
vivo,wefoundthatthepercentageofinsertionsinsidegeneswas
reduced after in vivo engraftment. PRE-GT in vitro samples
showed an enriched integration frequency inside genes both in
PBL-GT and HSC-GT (55.9 and 52.6%, respectively) while
POST-GT in vivo puriﬁed cell populations showed a lower
frequency of RIS into genes as compared to in vitro data in PBL-
GT T cells (51.3%) and in CD15þ cells (40.6%) or CD3þ cells
(40.7%, p<0.001. Test on proportions with Holm–Bonferroni
correction) from HSC-GT. In vivo T-cells and granulocytes from
HSC-GT displayed a slightly higher percentage of insertions
surrounding the TSS compared to the in vitro dataset, while
there is no indication of in vivo skewing in the PBL-GT samples.
Specific CIS were identified from PBL-GT and HSC-GT
We then analysed the presence of hotspots of integrations and
CIS in all our datasets in vitro and in vivo normalizing the size of
the clustering window for the number of integrations retrieved
in each group. CIS, deﬁned as clusters of two or more insertions,
were present already in vitro at the time of transduction both in
PBL-GT (43.4%) and HSC-GT (36.1%) groups (Table 2). The
proportion of insertions involved in clusters increased upon in
vivo selection only in CD3þ cells differentiated from transduced
HSC (44.8%, p<0.05. Test on proportions with Holm–
Bonferroni correction) while it decreased in those derived from
gene-corrected mature PBLs (34.0%, p<0.001). Integrations
from granulocytes did not display any particular clustering of
insertions around speciﬁc regions to the level present in vitro in
CD34þ cells (15.8%, p<0.05).
By comparing the two clinical trials, only a small number of
CIS genes (12 out of 474 total CIS) were in common between in
vitro transduced PBL or HSC while the majority of hotspots were
speciﬁc for the two target cells (Fig S1 of Supporting
Information). This low similarity is only slightly increased in
vivo where 14 out of 402 total hotspots were shared between
T-cell from HSC-GT and T cells from PBL-GT patients. Among
CIS genes retrieved in vivo only from HSC-GT, we found LMO2
and MDS1-EVI1. These genes were targeted both in CD3þ and
CD15þ cells from HSC-GT treated patients, while in vitro we
found only one insertion near LMO2 from transduced CD34þ
cells. The TCRA locus was instead a clear CIS only in PBL-GT
while no integration was retrieved in this region from HSC-GT
samples.
T-cell specific genes are favoured insertion sites in PBL-GT
To analyse the functions of genomic loci involved by RIS, we
collected data regarding the gene directly hit or the single gene
closest to each insertion site in order to assign one gene to one
integration. Hit gene lists for all insertion sites from PBL-GT,
HSC-GT and a random in silico dataset (n¼100,000) were
uploaded on the ingenuity pathways analysis (IPA) to look for
related biological functions.
Wecalculated thecontribution ofhit genes with respecttothe
functional categories listedin theIPA database.We analysedthe
frequency of hit genes listed in the two main categories
‘Haematologicalfunctions’and‘Immunefunctions’withrespect
to the remaining functions (Others; Fig 1A). As compared to
random reference both HSC-GT and PBL-GT displayed a higher
frequency of hit genes belonging to haematological functions.
PBL-GT displayed an even higher contribution of hit genes from
this category together with a signiﬁcant over-representation of
immune functions genes as compared to HSC-GT (37% vs. 28%,
p<0.001. Test on proportions with Holm–Bonferroni correc-
tion) and random (27%, p<0.001). The PBL-GT dataset
showed also a lower frequency of genes involved in other
functions, particularly in cardiovascular and nervous system.
These general preferences were conﬁrmed by restricting the
analysis to CIS genes in vitro and in vivo from PBL-GT and HSC-
GT (Fig S2 of Supporting Information).
Considering the nature of the cell type transduced in PBL-GT,
we extrapolated T-cell speciﬁc functions from the IPA library
and cross-compared these categories with our list of hit genes.
We found that genes involved in proliferation (p<0.001. Test
on proportions with Holm–Bonferroni correction), activation
(p<0.001), differentiation and development (p<0.05) of
T lymphocytes were clearly a preferential target for integrations
in PBL-GT when compared to the HSC-GT insertions and
random dataset (Fig 1B). We then looked closer at the canonical
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Table 2. Genomic distribution of MLV vector integration sites in PBL-GT and HSC-GT
Patient samples Inside gene (%) Outside gene (%) 10kb window on TSS (%) Clustered in CIS (%)
PBL-GT pre-GT CD3þ 55.9 44.1 27.6 43.4
PBL-GT post-GT CD3þ 51.3 48.7 23.6 34.0
PBL-GT total 54.1 45.9 26.1 39.8
HSC-GT pre-GT CD34þ 52.6 47.4 20.0 36.1
HSC-GT post-GT CD3þ 40.7 59.3 23.0 44.8
HSC-GT post-GT CD15þ 40.6 59.4 23.8 15.8
HSC-GT total 46.1 53.9 21.8 39.4
Randomly generated RIS 40.7 59.3 2.1 NA
Human genome 35.5 64.5 ND NA
Percentagesofintegrations invitroandinvivofromPBL-GT(blue)andHSC-GT(red)landinginsidegenes,outsidegenes,ina10kbwindowcentredonTSSofgenes
and involved in CIS in vitro and in vivo in PBL-GT or HSC-GT. Percentages relative to 100.000 random insertions and human genome reference are also shown for
comparison (ND, not done; NA, not available).
www.embomolmed.org EMBO Mol Med 3, 89–101  2011 EMBO Molecular Medicine 91T-cell receptor (TCR) signalling pathway from the IPA
library. As shown in Fig S3 of Supporting Information, the
TCR pathway was strongly and preferentially hit by integrations
derived from mature lymphocytes as compared to the ones
from HSC and their differentiated progeny. We also analysed
the contribution of hit genes to cytokine and interleukin
signalling pathways (Fig 2). T-cell speciﬁc pathways like
signalling of TCR, CD28 and IL-2 were signiﬁcantly targeted
only in PBL-GT as compared to the expected random frequency
calculated by IPA (p<0.05, Benjamini–Hochberg correction for
multiple testing). On the contrary, IL-6 signalling genes were
signiﬁcantly over-represented in the HSC-GT group of patients
and not in the PBL-GT one (p<0.05). We also divided the list
of hit genes according to their different representation in the
two GT trials (Fig S4 of Supporting Information). Again,
the preference for T-cell speciﬁc pathways was found only in
the PBL-GT speciﬁc hit genes and PBL-GT/HSC-GT commonly
hit genes.
No in vivo enrichment for ‘Cancer’ genes in PBL-GTand HSC-GT
We then studied the contribution of hit genes to the disease
category ‘Cancer’ (from IPA software) for all the integration
subsets (Fig S5 and Supporting Information ‘List of Cancer
Genes hit in PBL-GT and HSC-GT’). Proto-oncogenes were over-
represented in both trials when compared to randomly
generated integrations (n¼12,323 genes, p<0.05. Test on
proportions, Holm–Bonferroni correction). However, by com-
paring in vitro and in vivo data, we did not ﬁnd any signiﬁcant
enrichment in terms of hit proto-oncogenes among the different
subsetsinbothgroupsofpatients.Theindepthanalysisofgenes
related to myeloid leukaemia, lymphocytic leukaemia and
lymphomas in vitro in both the trials showed no signiﬁcant in
vivo skewing for any of these categories (Fig S5 and Supporting
Information‘ListofLeukaemia–LymphomaGeneshitinPBL-GT
and HSC-GT’). Although CD15þ cells from HSC-GT seem to
display a slightly higher contribution of myeloid leukaemia
and lymphocytic leukaemia genes, these differences were not
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Figure 1. Functions of genes hit by the MLV vector in PBL-GT and HSC-GT.
A. PhysiologicalfunctionsofgeneshitbyrandominsilicoinsertionsaswellasbyallHSC-GTandPBL-GTintegrationsinvitroandinvivo.Haematologicalfunctions
(orange), immune functions (light blue) and other functions (scale of grey) derive from a pool of categories listed in the Ingenuity pathway analysis software
(IPA) database. Percentages are calculated over the total number of hit genes involved in physiological functions. Asterisks indicate over-represented
categories with respect to random dataset (p<0.001. Test on proportions with Holm–Bonferroni correction).
B. T-cell functions genes hit by random in silico, HSC-GT and PBL-GT integrations. Percentages are calculated over the total number of hit genes. Categories
extrapolated from haematological and immune functions through the tool ‘effect on function’ from IPA software.
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tion dataset (Test on proportions, Holm–Bonferroni correction).
Differential gene expression profile influences vector
integrations in PBL and HSC
To getmore insight into thedifferential distribution of thevector
in the two transduced cell types, we analysed the expression
proﬁle of target cells at the time of transduction through HG-
U133A Affymetrix microarray chips. We then restricted the
analysis to the list of genes found to be hit in PBL-GT or HSC-GT
and compared the expression levels of hit genes to the overall
expression proﬁle in T cells and CD34þ cells (Fig 3A). We found
that the expression of hit genes was skewed towards the highest
expression categories in both trials as compared to the random
reference (p<0.0001 for all subgroups except for HSC CD15þ
with p¼0.052, Mann–Whitney test). In contrast, no signiﬁcant
skewing was found between the expression proﬁle of hit genes
retrieved from in vivo samples as compared to in vitro, in both
PBL-GT and HSC-GT groups.
By the comparison between the two Affymetrix chip datasets,
we were also able to extrapolate differentially expressed genes
in T cells and CD34þ cells at the time of transduction from the
distribution of differences (deltas) based on expression values
(Fig 3B). We identiﬁed a small fraction of probesets (225 out of
22,284; 1.01%) that were differentially expressed above an
arbitrary level of  3 delta robust multi-array averaging analysis
(RMA) values. A total of 105 probesets (corresponding to 89
genes) were found highly expressed in T cells at the time of
transduction, while 120 probesets (relative to 113 genes) were
speciﬁcally highly expressed in HSCs (Fig 3 heatmap and
SupportingInformation ‘Differentiallyexpressedgenes inTcells
vs. HSC’).
We then tried to assess how many integrations hit these two
groups of genes in PBL-GT or in HSC-GT (Fig 3B column graph),
considering that the calculated random frequency of insertions
is0.5%ineachgroup.IntegrationsfromPBL-GTinvolved19out
of89T-cellspeciﬁcallyexpressedgenes(35RIS,1.6%ofPBL-GT
insertions) and only 3 out of 113 CD34þ cells speciﬁc genes
(4RIS,0.2%ofPBL-GTinsertions).Onthecontrary,theHSC-GT
integration dataset contained 11 out of 113 of HSC speciﬁcally
expressed genes (23 RIS, 1.2% of HSC-GT insertions), whereas
T-cell expressed genes where signiﬁcantly less represented
(3 out of 89; 5 RIS, 0.3% of HSC-GT insertions; p<0.005. Test
on proportions, Holm–Bonferroni correction).
We then analysed the distribution of hit genes in vitro and in
vivo in both RIS datasets on the basis of their differential
expression levels between the two chips (Fig 3C). We found that
the insertions in HSC-GT versus PBL-GT were distributed among
the proﬁle of expression of hit genes in a signiﬁcantly different
fashion (p-value <0.001/<0.0001 Mann–Whitney test). More-
over, PBL-GT RIS were more skewed towards the T-cell
speciﬁcally expressed genes already in vitro at the time of
transduction, with no signiﬁcant difference as compared to the
in vivo insertions. HSC-GT insertions were instead more related
to CD34þ expressed genes both in vitro and in vivo, with CD3þ
cells displaying a distribution more similar to the random
reference as compared to in vitro dataset. These observations
were conﬁrmed and strengthened by limiting the analysis to CIS
genes in all the subgroups in vitro and in vivo (Fig S6 of
Supporting Information).
Cell-specific epigenetic marks correlate with integration
preferences
We then assessed whether the differential vector bias for some
loci was related to the overall chromatin accessibility of these
regions in the two different target cell types. In a ﬁrst analysis,
wecomparedthedistribution ofourintegrationstoDNaseIHSSs
mapped in human CD4þ T cells (Boyle et al, 2008). Overall, in
both trials the MLV vector displayed a strong preference to
integrate directly inside these regions as compared to the
random reference (2% randomly simulated RIS n¼100,000;
Fig 4A). Nonetheless, these features were hit in a signiﬁcantly
higher proportion in PBL-GT (34% of RIS from PBL-GT vs. 28%
from HSC-GT; p<0.001. Test on proportions with Holm–
Bonferroni correction) and integrations from PBL-GT were on
average more than two times closer to HSS mapped on T cells as
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Figure 2. Signalling pathways hit by retroviral integrations in PBL-GTand
HSC-GT. Percentages of genes belonging to different signalling pathways
calculated onthetotalnumberofhitgenes(
 p-value<0.05,Fisher’sexacttest
with B-H correction, random reference from IPA software). Frequency of hit
genes is shown by blue bars (PBL-GT) and red bars (HSC-GT).
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Figure 3. Correlation between expression profile of target cells and RIS in PBL-GT and HSC-GT.
A. Distribution of gene expression from HG-U133A affymetrix chips data (RMA values) in T-cells (upper panel) and in CD34þ cells (lower panel; random
references, black lines). The analysis is also restricted to the genes found to be hit in vitro and in vivo from PBL-GT as well as in vitro and in CD3þ and CD15þ
cells in vivo from HSC-GT.
B. Heatmap of differentially expressed genes in T cells and CD34þ cells. The column graph below shows the percentage of insertions from PBL-GT (blue column)
and HSC-GT (red column) landing in these two group of genes as compared to random expected frequencies from HG-U133A probesets (
 p<0.05,
  p<0.005.
Test on proportions, Holm–Bonferroni correction).
C. Differential gene expression of hit genes in PBL-GT and HSC-GT. The dotted line in correspondence with þ3a n d 3 value refers to the threshold used for the
comparative analysis of panel (B). Gene expression in target cells is represented in a scale of differential expression rate (RMA values) on y-axis for all genes in
HG-U133Aaffymetrix chip(greydots),hit genes invitroand invivo inCD3þand CD15þcellsfrom HSC-GT(red, orangeand yellow dots,respectively)aswell as
in vitro and in vivo in PBL-GT (dark blue and light blue dots;
  p<0.001,
   p<0.0001, Mann–Whitney test).
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respectively; p<0.0001 Mann–Whitney test; Fig 4B).
To further dissect the relationship between integration
preferences and chromatin status, we took advantage of the
data available on histone methylation proﬁle in CD4þ T cells
and CD133þ/CD34þ haematopoietic stem/progenitor cells
(HSC/HPC; Barski et al, 2007; Cui et al, 2009). We analysed
thedistancesofeachofthesefeaturesfromeveryintegrationsite
considering a  45kb window centred on RISs both from PBL-
GT and HSC-GT in vitro and in vivo. This analysis was
performed on histone methylations mapped both on T cells and
HSC/HPC (Fig 5A). Remarkably, PBL-GT and HSC-GT datasets
showed a higher contribution of integrations close to histone
modiﬁcations associated with open chromatin state and gene
activation, like H3K4me1 and H3K27me1 and with active TSS
like H3K4me3. These preferences were present at the time of
transduction and were maintained in POST-GT samples. On the
other hand, histone methylations associated with heterochro-
matin regions, like H3K9me3, were disfavoured by the MLV
vector equally in both cell types. Strikingly, the disfavouring for
H3K27me3 was cell-speciﬁc, since it was evident only when the
RIS of one trial were compared to this feature mapped on their
relative target cell. On the contrary, when compared to the
H3K27me3 mapped on the unrelated target cell, the distribution
of RIS related to this histone modiﬁcation was more similar to
the random reference. A complete analysis on other epigenetic
features is shown in Figs S7 and S8 of Supporting Information.
We also subdivided the insertional datasets in vitro and in vivo
in two subgroups containing CIS insertions and NOT CIS
insertions, respectively, and we extended the analysis of histone
methylation density distribution on each of these loci (Fig S9 of
Supporting Information). Integration sites from HSC-GT in vivo
CD15þ cells were excluded in this analysis due to the small
number of CIS retrieved. The distribution of histone methyla-
tionsaroundCISwasoverallsimilartotheregionshostingsingle
integrationevents(NOTCIS).Wefoundadditionalconﬁrmation
of cell-speciﬁc disfavouring for H3K27me3 modiﬁcation,
although CIS from HSC-GT CD3þ cells in vivo showed a
different probability density distribution of this feature, more
similar to the random reference, as compared to NOT CIS
integrations and insertions from CD34þ cells in vitro.
Finally, we selected two cell-speciﬁc hotspots, LMO2 and
TCRA, to study the local epigenetic landscape in relation to the
speciﬁc insertion sites (Fig 5B). The LMO2 region, that was
found to be hit only in HSC-GT, displayed a clear heterochro-
matic conﬁguration (high H3K27me3 density) in T cells being
instead open in HSC/HPC. On the other hand, the TCRA locus,
which was an hotspot in PBL-GT but did not host any HSC-GT
insertions, showed in correspondence to insertion site cluster a
strong signal of open chromatin conformation (high H3K4me3
density) in T cells while it is mostly in closed conﬁguration in
HSC/HPC.
DISCUSSION
Integration site analysis has now become a critical tool to
monitor the activity of retroviral vectors on in vivo selection of
patient clones (Aiuti et al, 2007; Deichmann et al, 2007; Ott et al,
2006). In view of the adverse events that occurred in the SCID-
X1 GT clinical trials, a number of studies have focused their
attention on the inﬂuences of the vector on neighbouring genes
(Hacein-Bey-Abinaetal,2003b,2008;Howeetal,2008;Maruggi
et al, 2009; Ott et al, 2006) as well as how these could lead to
clonal dominance and possibly to malignant transformation
(Deichmann et al, 2007; Kustikova et al, 2007; Montini et al,
2006, 2009). In contrast, the impact of host cell genetic/
epigenetic conditions on vector target site selection in vitro and
in vivo is often overlooked in GT clinical studies.
Here, we had the unique opportunity to compare integration
sitesintwo GTtrials, intheabsence ofadverseevents andmajor
clonal expansions, sharing the same MLV vector gene transfer
approach and the same ADA-SCID genetic background and
only differing in the transduced cell type infused in patient,
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Figure 4. Comparison between insertion sites and T-cell DNase HSSs distribution.
A. Percentages of integrations landing inside a T-cell HSS in PBL-GT, HSC-GT and random in silico insertions.
B. Average distance in bp from the closest T-cell HSS of RIS from PBL-GT (blue bar), HSC-GT (red bar) and random in silico insertions (grey bar; Mean and SEM,
   p<0.0001 Mann–Whitney test).
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Figure 5. Comparison between histone tail modifications distribution in T-cell and HSC versus RIS in PBL-GT and HSC-GT.
A. Distribution of distances from six different histone tail modifications (H3K4me1, H3K4me3, H3K9me3, H3K27me1, H3K27me3 and H3K36me3) in a  45kb
window centred on RIS from PBL-GT, HSC-GT and random database. Probability density of distances is represented by a gradient from blue (low) to yellow
(high). All insertion datasets are compared to the six histone tail modifications mapped in T cells or in HSC/HPC.
B. Distribution of four histone modifications in a 350kb window centred on LMO2 (left) and TCRA (longest transcript; right). Signals of four histone modifications
mappedontheselectedwindows arerepresentedforTcellsas bluecolumnsbelow theaxis andforHSC/HPCas redcolumns abovetheaxis ofthemirror graph.
Insertion sites are shown as blue lines (RIS from PBL-GT) and as red lines (RIS from HSC-GT).
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and HSC-GT, respectively. Our high-throughput analyses
revealed a cell-speciﬁc vector preference that is related to the
host cell status in terms of chromatin state and transcriptional
activity at the time of transduction. Long-term follow up of
treated patients showed that this cell-speciﬁc pattern is overall
maintained in vivo.
The number of unique insertions retrieved from the different
samples analysed correlate well with the percentage of vector
positive cells calculated by q-PCR. As expected, the contribution
of insertions from granulocytes in HSC-GT patients was lower
with respect to other lineages, having proportions of transduced
cells ranging between 1.1 and 5.8%. Nevertheless, the
integration dataset from granulocyte cells is more complex
andabundantthaninotherstudiesonGTclinicaltrials(Ottetal,
2006; Wang et al, 2010). In addition, in the present work, we
collected a relevant number of insertions from PRE-GT samples
(1365 RIS and 887 RIS from PBL-GT and HSC-GT, respectively)
allowing a coherent comparison of in vitro data with integration
sites detected long-term in patients. We were thus able to better
discriminate between intrinsic insertional preferences in target
cells before infusion and selective pressures or vector-driven
bias after in vivo engraftment and selection.
Integrations inside genes were less represented in POST-GT
samples, suggesting that clones carrying insertions into coding
regions affecting cell survival were negatively selected in vivo.
In addition, when focusing on CIS we found that clusters of
insertions were present at a relevant frequency already at the
time of transduction both in PBL-GT and HSC-GT, but the
contribution of integrations involved in CIS increased in CD3þ
cells differentiated from transduced progenitors of HSC-GT
patients. This in vivo skewing could be explained by a positive
role of vector position on growth-promoting genes, such as
LMO2 and MDS1-EVI1. Nonetheless, the polyclonality of the RIS
and the TCR repertoire as well as the lack of expansion of LMO2
insertions by clonal tracking over time (Aiuti et al, 2007) would
suggest that the ﬁnding of a CIS in the proximity of a proto-
oncogene is not necessarily linked to aberrant proliferation in
vivo. Although we found only one RIS in the LMO2 locus in vitro
in HSC-GT in the present dataset, it should be noted that this
regionhas been previouslyshown tobe ahotspot ofintegrations
in CD34þ cells (Aiuti et al, 2007; Cattoglio et al, 2007). One
could also argue that clones carrying insertions in HSC active
loci would have a survival advantage due to a better
detoxiﬁcation from toxic metabolites, particularly in the early
phases after GT during which purine metabolites are elevated
due to enzyme replacement therapy discontinuation in
combination with the effects of chemotherapy (Aiuti et al,
2009). Monitoring these clones in longer follow up will provide
clearer information about a possible effect of vector on clonal
dynamics.
The highest overlap of hotspots (6.6% of CIS genes) was
found comparing the integrations from in vitro and in vivo
lymphocytes in PBL-GT. On the other hand, few CIS genes were
in common between lymphocytes and their transduced
progenitors in HSC-GT, likely as a result of the complex
developmental path from CD34þ cells to T cells.
Having observed differential genomic distribution and
clustering of insertions in the two GT trials, we hypothesized
that the different status of the two target cell types (lymphocytes
and HSC/HPC) could have inﬂuenced in a cell-speciﬁc fashion
the integration proﬁle of MLV vector in vitro at the time of
transduction and in vivo after selection. Our ﬁnding that MLV
insertions from PBL-GT showed a strong preference for
‘immune functions’ genesandalowercontribution ofcategories
unrelated to haematological/immune system was a ﬁrst
conﬁrmation of a cell-dependent integration proﬁle. This
observation was further strengthened when we looked deeper
at T-cell speciﬁc functions and pathways, which were
signiﬁcantly hit by integrations only in PBL-GT and not in
HSC-GT. Analysis of the ‘Cancer’ category and leukaemia/
lymphoma related genes from IPA software showed a higher
contribution of hit genes with respect to random, with no
signiﬁcant in vivo selection for these categories, suggesting that
integrations in these loci have not provided any growth
advantage to transduced cells. It should also be noted that
the deﬁnition of ‘Cancer-related’ genes is somehow arbitrary
and a relevant number of genes belonging to this category are
also involved in physiological functions of haemopoietic
system.
We then wondered whether cell-speciﬁc preferences were
linked to the expression proﬁle of the two different target cells at
the time of transduction. In line with previous reports on
integration studies in haematopoietic cells (Aiuti et al, 2007;
Cattoglio et al, 2007; Mitchell et al, 2004; Recchia et al, 2006),
MLV vector favoured genes belonging to higher expression
categories in both trials in vitro, without signiﬁcant in vivo
skewing. By the comparison of the expression proﬁle in the two
target cell types we found that MLV vector favoured genes
speciﬁcally expressed inT cells inPBL-GT and genes speciﬁcally
expressed in CD34þ cells in HSC-GT. Interestingly, the
comparison between integrations in CD3þ cells in vivo from
HSC-GT versus PBL-GT revealed that the same kind of lymphoid
cellsdisplayedinthetwotrialsacompletelydifferentintegration
proﬁle that was related to the type of transduced cells from
which they derived in vivo.
However, gene expression is not the only mechanism driving
integration preferences of MLV vector. Indeed, we found a
substantial number of genes hit by the vector but not
signiﬁcantly expressed in the two target cells and a relevant
overlap in the expression pattern of hit genes from the different
sample subsets, suggesting that the differential expression
proﬁle could not account per se to the clustering of insertions in
speciﬁc regions of the genome. This observation extends the
information from previous studies on MLV insertional hotspots
(Cattoglio et al, 2007; Recchia et al, 2006) and is also supported
by our analysis of expression proﬁles of CIS genes (Fig S6 of
Supporting Information). We therefore hypothesized that the
overallaccessibilityofthegenome atthetimeoftransduction,of
which ‘gene expression’ is an indicator, could play a more
general role in inducing the cell-speciﬁc insertional preferences
ofMLVvector.Forthisreason,wecorrelatedinsertionsiteswith
other epigenetic features accounting for different chromatin
conformations.
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as well as with the presence of active DNA binding sites for
regulatory proteins and have been associated with MLV vectors
insertions in HeLa cells and CD34þ cells (Lewinski et al, 2006;
Wang et al, 2010). Our results show that on average PBL-GT
insertions were two times closer to HSS mapped on T cells
(Boyle et al, 2008) as compared to HSC-GT RIS, thus accounting
again for an additional mechanism linked to cell-speciﬁc
preferences of MLV vector.
Histonemodiﬁcations areotherimportantepigeneticmarkers
of open/closed chromatin state and their distribution was
recently mapped through ChIP-Seq technique both in human
T cells and HSC/HPC (Barski et al, 2007; Cui et al, 2009).
Correlation of insertion sites and histone methylations was
previously shown in recent studies (Brady et al, 2009; Wang
et al, 2010). Our work provides novel information on how the
general chromatin state of two different haematopoietic cells
inﬂuences vector integrations by the cross-comparison of vector
insertion proﬁles in PBL-GT and HSC-GT with several histone
marks mapped in both target cell types. As compared to random
distribution, insertion sites were preferentially located in
proximity of histone modiﬁcations associated with an open
chromatin state(Fig5A).The strongestpreferencewasnotedfor
H3K4me3, a modiﬁcation that is mainly present in correspon-
dence of TSS of genes (Barski et al, 2007), similarly to recent
observations in the X-SCID GT trial (Wang et al, 2010) thus
indicating that this is a common feature of MLV vectors.
Importantly, no cell-speciﬁc behaviour was found when
comparing H3K4me3 mapped in the two target cells. One
could envisage that, at a genome wide level, many of these
H3K4me3 modiﬁcations share the same position in both T cells
and CD34þ cells. Indeed, in a recent work on chromatin
remodelling upon lymphoid differentiation, histone modiﬁcations
involved in chromatin decondensation related to lymphoid-
afﬁliated genes were already detected in HSCs (Maes et al,
2008). Histone methylations associated with heterochromatic
conformations are, on the other hand, disfavoured by MLV
vector integrations. Strikingly, among all histone markers, we
discovered that H3K27me3 alone represents a key epigenetic
determinant of cell-dependent integration proﬁle of MLV
vector, since it was the only modiﬁcation that was disfavoured
in a cell-speciﬁc fashion. These results are in agreement with
the ﬁndings of in vitro studies showing that H3K27me3
distribution was signiﬁcantly changed upon differentiation of
haematopoietic progenitor cells (Cui et al, 2009) and from the
analysis of epigenetic marks in distinct lymphoid lineages
were the genomic association with H3K27me3 signals was
both gene- and cell-speciﬁc (Wei et al, 2009). Our results
support the concept that the different distribution of these
cell-speciﬁc ‘closed windows’ in the genome of our target cells
is indirectly driving the vector to ‘open windows’ associated
with general chromatin accessibility and gene expression. In
this view, the bias of MLV for some speciﬁc active loci
could also be the consequence of chromatin inaccessibility
to integration events of other regions. It should be also noted
that the majority of the histone marks analysed, even when
mapped in correspondence of genes, are not necessarily
associated to TSS, a preferential target for MLV vectors, thus
suggesting a general active role of epigenetic signals also on
integrations retrieved inside coding regions or collected from
intergenic spaces. The different inﬂuence of some of these
signals in T cells and HSC/HPC on integration events is further
evident when focusing on LMO2 and TCRA regions that were
speciﬁc insertional hotspots in HSC-GT and PBL-GT, respec-
tively (Fig 5B). By the analysis of CIS and NOT CIS loci we found
that the cell-speciﬁc disfavouring for H3K27me3 signal is a
general rule of integration site selections both in hotspots or
regions hosting single integration events (Fig S9 of Supporting
Information). Nevertheless, it is interesting to notice that CIS
derived from HSC-GT in vivo CD3þ cells displayed a different
distributionofthishistonemodiﬁcationascomparedtoNOTCIS
subset and to the CD34þ cells in vitro from which they derived.
This is in agreement with the results regarding the transcrip-
tional activity of CIS genes (signiﬁcantly different between HSC
in vitro and T cells in vivo from HSC-GT patients, Fig S6 of
Supporting Information) and again points to a more complex
mechanism of physiological selection of insertions upon in vivo
differentiation.
In conclusion, our high-throughput analysis shows that
MLV vector displays integration preferences that are cell-
speciﬁc and closely related to the genomic and chromatin
state of target cells at the time of transduction. Most of these
insertional features are mirrored in in vivo patient samples
without showing any particular deviation from in vitro vector
distribution even several years after GT. These results better
deﬁne the ‘physiological’ MLV vector behaviour in GT patients
treated with different gene-corrected cells in absence of
adverse events, thus providing information of reference for
the follow up of ongoing clinical trials based on the use of
gammaretroviral vectors and for the future design of novel
gene transfer approaches for genetic correction of hemato-
poietic cells.
MATERIALS AND METHODS
Patients and clinical trials
ADA-SCID lacking HLA-identical sibling donors were enrolled in the
clinical trials. PBL-GT patients were enrolled between 1992 and 1998
in a phase I/II clinical trial with repeated infusions of transduced
autologous PBL (#NCT00599781) PBL-GT Pt1, 2, and 3 have been
previously described (Aiuti et al, 2002b; Bordignon et al, 1995) while
Pt4 received a similar treatment (Aiuti et al, in preparation). HSC-GT
patients were enrolled between 2002 and 2005 in a phase I/II clinical
trial for ADA-SCID GT with transduced autologous CD34þ cells
(#NCT00598481) and HSC-GT Pt4-7 were previously described (Aiuti
et al, 2009). For both groups the GIADAl retroviral vector encoding ADA
cDNA under the MLV long terminal repeat (LTR) promoter was used
(Aiuti et al, 2002b). Vector production and transduction protocol have
been previously described (Aiuti et al, 2002a,b, 2009). The clinical
trials described in this study were approved by San Raffaele Scientific
Institute Ethical Committee and Italian national regulatory autho-
rities. All patients signed the informed consent to the experimental
treatment and follow up analyses.
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In vitro samples were derived from a fraction of transduced T cells or
CD34þ cells that were infused in patients, kept in culture for
additional 3 days after trasduction.
In vivo cell subsets were purified from peripheral blood of ADA-SCID
patients as previously reported (Aiuti et al, 2007). To detect the
presence of the vector in patient cells we extracted genomic DNA by
QIAamp DNA Blood Mini kit or Micro kit (Qiagen) and we performed
qPCR for vector positivity with primers specific for Neo
R reporter gene
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as shown
previously (Aiuti et al, 2002a; Cassani et al, 2008). Percentage of
transduced cells were calculated on the basis of a standard curve and
expressed as proportion of cells carrying the Neo
R gene.
Analysis of vector integration
To collect integration sites from patient samples we performed LM-
PCR with the use of MseI enzyme as elsewhere reported (Aiuti et al,
2007; Wu et al, 2003). Fasta sequences from insertions previously
retrieved with the same technique in CD3þ cells of HSC-GT Pt4 and
Pt5 were also added to the analysis (Aiuti et al, 2007). We also set up
another protocol on the basis of LAM-PCR technique previously
described (Schmidt et al, 2007) which consisted in two steps of linear
amplifications using two 50-biotynilated primers designed in forward
direction on MLV LTR (MLV1: 50-GACTGAGTCGCCCGGGTACCCGTGT-30
and MLV2: 50-CCAATAAACCCTCTTGCAGTTGCA-30) under the following
conditions: 958C, for 5min, 50 cycles at 958C for 45s, 608C for 45s
and 728C for 1.5min, and a final step at 728C for 10min. After ligation
o/n with streptavidine magnetic beads (Invitrogen Dynabeads) linear
amplified products went through a Klenow-mediated second strand
reconstitution, MseI digestion and linker ligation. Fragments were
then detached from beads with 15min incubation with NaOH 0.1M
at 258C, exponentially amplified with primers for LTR and linker as in
LM-PCR protocol and sanger sequenced. In addition, we retrieved
integration sites through the combination of LAM-PCR with the use of
up to four enzymes (TSP509I, Hinp1l, HpyCH4IV and MseI) and 454-
pyrosequencing (Roche) technique as described in a previous work
(Bushman et al, 2008; Howe et al, 2008; see also Supporting
Information ‘Integration sequences from PBL-GT and HSC-GT’, ‘List of
CIS from HSC-GT’, ‘List of CIS from PBL-GT’). In total, 6% of the
integrations (137 out of 2198) from PBL-GT and 2% of the
integrations (47 out of 1959) from HSC-GT were retrieved with MseI
enzyme only, while the majority derived from the use of four
restriction enzymes in both the trials.
Bioinformatics and statistical analysis
Details of bioinformatics and statistical methods used for the mapping
of vector integrants and the analysis of hit gene functions as well as
correlations of vector insertions with expression profile and epigenetic
statuses of target cells are available in Supporting Information
‘Bioinformatics and Statistical analysis’. Expression data from micro-
arrays experiments are deposited on ArrayExpress public database
(http://www.ebi.ac.uk/arrayexpress/).
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The paper explained
PROBLEM:
Retroviral vectors have been used as effective tools to transfer
therapeutic genes for the treatment of haematological inherited
disorders. Studies on how the vectors integrate into the host
genome of different cell types and how gene-corrected cells
engraft and survive long-term in patients are crucial to provide
information on the safety and efficacy of GT approaches.
RESULTS:
We studied the properties of genomic integration sites of a
gammaretroviral vector in haematopoietic cells from GT-treated
patients affected by adenosine deaminase deficient-severe
combined immunodeficiency (ADA-SCID), treated either with
mature lymphocytes or haematopoietic stem cells, in clinical
contexts free from adverse events. We analysed the influence of
target cell type on vector integrations both at the time of gene
transferand yearsafterinfusioninGTtreatedpatients.Ourstudy
uncovered a cell-specific insertion profile of retroviral vector
dependent on functional and transcriptional activity as well as
on epigenetic and chromatin conformations of host genome.
IMPACT:
This work unveiled the genomic features influencing the
‘physiological’ integration site selection of a gammaretroviral
vectors in two different target cell types, providing crucial
information for the follow up of current and future GT trials
based on genetic modifications of haematopoietic cells.
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